Squamous Carcinoma Clinical Trials

17 recruitingLast updated: July 2, 2026

There are 17 actively recruiting squamous carcinoma clinical trials across 11 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Cincinnati, Ohio, United States, Madison, Wisconsin, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


Squamous Carcinoma Trials at a Glance

17 actively recruiting trials for squamous carcinoma are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Cincinnati, Madison, and Atlanta. Lead sponsors running squamous carcinoma studies include National Cancer Institute (NCI), Christian Hinrichs, and Revolution Medicines, Inc..

Browse squamous carcinoma trials by phase

Treatments under study

About Squamous Carcinoma Clinical Trials

Looking for clinical trials for Squamous Carcinoma? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Squamous Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Squamous Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 3

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma+3 more
National Cancer Institute (NCI)1,210 enrolled1150 locationsNCT04267848
Recruiting
Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Locally Advanced Cervical Adenocarcinoma+5 more
National Cancer Institute (NCI)336 enrolled289 locationsNCT07061977
Recruiting
Phase 1

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and NeckHNSCCSquamous Cell Cancer of Head and Neck (SCCHN)+8 more
Vanderbilt-Ingram Cancer Center40 enrolled1 locationNCT07460765
Recruiting
Phase 3

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.900 enrolled13 locationsNCT07491445
Recruiting
Phase 2

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell CarcinomaResectable Pancreatic CarcinomaResectable Pancreatic Adenocarcinoma+4 more
National Cancer Institute (NCI)152 enrolled454 locationsNCT04858334
Recruiting
Phase 3

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.670 enrolled3 locationsNCT07621718
Recruiting
Phase 1Phase 2

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Cervical CancerAnal CancerPenile Cancer+14 more
Christian Hinrichs15 enrolled2 locationsNCT05639972
Recruiting
Phase 2

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Cervical CancerMetastatic CancerAnal Cancer+18 more
Christian Hinrichs20 enrolled3 locationsNCT05686226
Recruiting
Phase 2

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Squamous Cell CarcinomaAdvanced Non-Small Cell Lung CancerAdvanced NSCLC+2 more
National Cancer Institute (NCI)85 enrolled1 locationNCT02133196
Recruiting
Phase 2

Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Late-stage Resectable Esophageal Squamous Carcinoma
The First Affiliated Hospital of Henan University of Science and Technology164 enrolled1 locationNCT07622797
Recruiting
Phase 1

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Colorectal, CancerHormone Receptor-Positive Breast CarcinomaGastric Adenocarcinoma+6 more
Avacta Life Sciences Ltd174 enrolled3 locationsNCT07454642
Recruiting
Phase 3

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

Cervical CarcinomaAdenocarcinomaAdenosquamous Carcinoma
Institut Claudius Regaud510 enrolled35 locationsNCT05581121
Recruiting
Phase 2

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Pancreatic AdenocarcinomaPancreatic Neuroendocrine TumorGastrointestinal Neuroendocrine Tumor+4 more
University of Michigan Rogel Cancer Center66 enrolled3 locationsNCT05988918
Recruiting
Phase 2

Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda

Cervical CancerCervix CancerCervical Adenocarcinoma+2 more
Uganda Cancer Institute278 enrolled1 locationNCT07276360
Recruiting
Phase 1Phase 2

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma+1 more
Jonsson Comprehensive Cancer Center35 enrolled4 locationsNCT06543576
Recruiting
Phase 1

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic AdenocarcinomaPancreatic Adenosquamous Carcinoma
Diakonos Oncology Corporation18 enrolled3 locationsNCT04157127
Recruiting
Phase 2

Neoadjuvant SBRT in Localized Advanced HNSCC

Head and Neck Squamous Carcinoma
Jiang Feng81 enrolled1 locationNCT06306846